Education
About Us
Working with TipRanks
Follow Us
2seventy bio (TSVT)
NASDAQ:TSVT
TSVT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.29 - $5.90
Previous CloseN/A
Volume53.84K
Average Volume (3M)1.82M
Market Cap
$260.12M
Enterprise Value$222.82M
Total Cash (Recent Filing)$71.24M
Total Debt (Recent Filing)$243.72M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
May 08, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding52,338,383
10 Day Avg. Volume760,960
30 Day Avg. Volume1,821,888
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.60
Price to Cash Flow (P/CF)-6.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.89
Enterprise Value/Ebitda-2.27
Forecast
1Y Price Target
$6.33Price Target Upside27.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
2seventy bio News
PremiumCompany Announcements
2seventy bio Reports 2024 Earnings Amid BMS Merger
PremiumPre-Earnings
Is TSVT a Buy, Before Earnings?---
Bulls Say, Bears Say
Bulls Say
Acquisition PremiumThe transaction price implies a ~80% premium to TSVT's closing price of $2.80/share.
Cash Position2Seventy ended the quarter with $192 million in cash, cash equivalents, and marketable securities and reiterated a cash runway beyond 2027 and a path to profitability by 2025.
Bears Say
Competitive PressureMarket uncertainty exists with Kite and Arcellx's expected launch of a third BCMA CAR-T, threatening Abecma's niche.
Revenue Challenges2seventy's top-line revenue fell short of expectations, reflecting Abecma's gross profit.
---
Ownership Overview
10.23% Insiders
11.03% Mutual Funds
39.03% Other Institutional Investors
26.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TSVT FAQ
What was 2seventy bio’s price range in the past 12 months?
2seventy bio lowest stock price was $2.29 and its highest was $5.90 in the past 12 months.
What is 2seventy bio’s market cap?
2seventy bio’s market cap is $260.12M.
When is 2seventy bio’s upcoming earnings report date?
2seventy bio’s upcoming earnings report date is May 08, 2025 which is in 32 days.
How were 2seventy bio’s earnings last quarter?
2seventy bio released its earnings results on Mar 25, 2025. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.202 by -$0.168.
Is 2seventy bio overvalued?
According to Wall Street analysts 2seventy bio’s price is currently Undervalued.
Does 2seventy bio pay dividends?
2seventy bio does not currently pay dividends.
What is 2seventy bio’s EPS estimate?
2seventy bio’s EPS estimate is -0.17.
How many shares outstanding does 2seventy bio have?
2seventy bio has 52,338,383 shares outstanding.
What happened to 2seventy bio’s price movement after its last earnings report?
2seventy bio reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.202. Following the earnings report the stock price went up 0.202%.
Which hedge fund is a major shareholder of 2seventy bio?
Currently, no hedge funds are holding shares in TSVT
---
2seventy bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.33 (27.36% Upside)
$6.33 (27.36% Upside)
Blogger Sentiment
Neutral
TSVT Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 520.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $80.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.9%
Last 30 Days ▼ 11.0%
Last 30 Days ▼ 11.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.20%
12-Months-Change
Fundamentals
Return on Equity
-24.56%
Trailing 12-Months
Asset Growth
-15.19%
Trailing 12-Months
Company Description
2seventy bio
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
---
TSVT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in ABECMA revenues and significant cost reductions, indicating positive progress towards breakeven. Despite seasonal challenges and market competition, the company remains optimistic about future growth and operational efficiency.Read More>---
TSVT Stock 12 Month Forecast
Average Price Target
$6.33
▲(27.36% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Sangamo Biosciences
―
Bluebird Bio
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering TSVT
1 Year
1 Year Success Rate
3/8 ratings generated profit
1 Year Average Return
-23.16%
reiterated a buy rating 11 months ago
Copying John Newman's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -23.16% per trade.
---